CStone Pharmaceuticals' stock surged 5.04% during the intraday session, following the release of highly positive research reports from two major international investment banks.

Jefferies maintained its "Buy" rating on the company with a target price of HK$20, while Goldman Sachs also reiterated a "Buy" rating with a target of HK$9.44. Both firms highlighted the promising clinical data and commercial prospects of CStone's core investigational product, the PD-1/VEGF/CTLA-4 trispecific antibody CS2009. The reports emphasized that CS2009 has demonstrated outstanding efficacy and a favorable safety profile across multiple cancer indications, positioning it as a key future value driver.

Analysts pointed to specific clinical results, including a 90% objective response rate in first-line non-small cell lung cancer patients, as evidence of the drug's strong competitiveness. The favorable safety profile is expected to support the advancement of Phase III trials and reduce commercialization uncertainties. Looking ahead, multiple key catalysts are anticipated, including updated data presentations at major oncology conferences and the initiation of global Phase III studies by the end of 2026, which analysts believe could lead to a potential reassessment of the company's valuation.